Urinary citrate and renal stone disease: The preventive role of alkali citrate treatment

Archivio Italiano di Urologia e Andrologia

Volumn 81, Issue 3, 2009, Pages 182-187

  Caudarella, Renata ^a   Vescini, Fabio ^b  

^a Fondazione Villa Maria   (Italy)

^b Ospedale Civile di Gorizia   (Italy)

Author keywords

Alkali therapy; Citrate; Stone disease

Indexed keywords

CALCIUM ION; CALCIUM OXALATE; CALCIUM SALT; CITRATE CALCIUM; CITRATE POTASSIUM; CITRIC ACID; MAGNESIUM CITRATE; TAMM HORSFALL GLYCOPROTEIN;

ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE FRAGILITY; BONE MASS; CALCIFICATION; CALCIUM OXALATE STONE; CALCIUM STONE; CITRIC ACID CYCLE; CLINICAL PRACTICE; CLINICAL TRIAL; CRYSTALLIZATION; DISSOLUTION; DRUG WITHDRAWAL; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCITRAURIA; HYPOKALEMIA; KIDNEY CLEARANCE; METABOLIC ACIDOSIS; METABOLIC BONE DISEASE; METABOLIC DISORDER; NEPHROLITHIASIS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POTASSIUM URINE LEVEL; PRESCRIPTION; RECURRENT DISEASE; STARVATION; URINALYSIS; URINARY EXCRETION; URINE LEVEL; URINE PH;

CITRATES; HUMANS; KIDNEY CALCULI; POTASSIUM CITRATE;

EID: 70350501371     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Caudarella R, Vesdni F, Buffa et al. Citrate and minerai metabolism: kidney stones and bone disease. Front Biosci 2003; 8:s1084.
2. Jehle S. Jehle S, Zaneti A, Muser J, Hulter HN, Krapf R. Partial neutralization of the atidogenic Western diet with potassium titrate increases bone mass in postmenopausal women with osteopenia. J Am Soc Nephrol 2006; 17:3213. (Pubitemid 44707783)
3. Sebastian A, Harris ST, Ottaway JH, Todd KM, Morris Jr C. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med 1994; 330:1776. (Pubitemid 24177612)
4. Marangella M, Di Stefano M, Casalis S, Berutti S, D'Amelio P. Isaia GC. Effects of potassium titrate supplementation on bone metabolism. Calcif Tissue Int 2004; 74:330. (Pubitemid 38480856)
5. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989; 245:855. (Pubitemid 19223662)
6. Sakhaee K, Alpern R, Jacobson HR, Pak CY. Contrasting effects of various potassium salts on renal citrate excretion. J Gin Endocrinol Metab 1991; 72:396. (Pubitemid 21921706)
7. Lemann Jr J. Relationship between urinary calcium and net acid excretion as determined by dietary protein and potassium: a review. Nephron 1999; 81(Suppl 1):18.
8. Bushinsky DA. Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Am J Physiol 1996; 271:F216.
9. Sakhaee K, Williams RH, Oh MS et al: Alkali absorption and titrate excretion in calcium nephrolithiasis JBMR 1993; 8:789.
10. Hamm LL. Citrate handling by the kidney. Kidney Int 1990; 38: 728
11. Pajor AM. Sequence and functional characterization of a renal sodium/dicarboxylate cotransporter. J Biol Chem 1995; 270:5779.
12. Okamoto N, Aruga S, Matsuzaki S, Takahashi S, Matsushita K and Kitamura T. Associations between renal sodium-citrate cotransporter (hNaDC-1) gene polymorphism and urinary titrate excretion in recurrent renal caldum stone formers and normal controls. Int J Urol 2007; 14:344. (Pubitemid 46669036)
13. Caudarella R, Buffa A, Vestini F. Citrates in Nephrolithiasis. Clinical cases in Mineral and Bone Metabolism 2004; 1:53.
14. Pak CYC. Citrate and renal calculi: un update. Miner Electrolyte Metab. 1994; 20:371.
15. Renata Caudarella. Studio metabolico e terapia medica della calolosi renale: retaggio del passato o scelta opportuna per il future? La Nefrolitiasi nel terzo millennia Una patologia di pertinenza multidisciplinare. Fiuggi, 6 novembre 2004. (oral presentation)
16. th. Gerron GG, Bleier J. Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab 1982; 55:1052.
17. Minisola S, Rossi W, Patitti MT, et al. Studies on citrate metabolism in normal subjects and kidney stone patients. Miner Electrolyte Metab 1989; 15:303. (Pubitemid 19221283)
18. Fegan J, Khan R, Poindexter J, Pak CYC. Gastrointestinal citrate absorption in nephrolithiasis. J Urol 1992; 147:1212.
19. Aruga S, Wehrli S, Moe OW, et al. Chronic acidosis increases NaDC-1 mRNA and protein abundance in rat kidney. Kidney Int 2000; 58:206. (Pubitemid 30429865)
20. Levi M, McDonald LA, Preisig PA, Alpern RJ. Chronic K depletion stimulates rat renal brush-border membrane Na-citrate cotransporter. Am J Physiol 1991; 261:F767.
21. Windus DW, Cohn DE, Heifets M. Effects of fasting on titrate transport by the brush-border membrane of rat kidney. Am J Physiol 1986;251:F678. (Pubitemid 17176461)
22. Breslau NA, Brinskley L, Hill KD, Pak CYC. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66:140.
23. Hess B, Michel R, Takinen D, Ackermann D, Jaeger Ph. Risk factors for low urinary titrate in calcium nephrolithiasis: low vegetable fibre intake and low urine volume to be added to the list. Nephrol Dial Transplant 1994; 9:642. (Pubitemid 24192950)
24. Pak CYC. Citrate and renal calculi: new insights and future directions. Am J Kidney Dis 1991; 17:420.
25. Nicar MJ, Skurla C, Sakhaee K, Pak CYC. Low citrate excretion in nephrolithiasis. Urology 1983; 21:8.
26. Parks JH, Ruml LA, Pak CYC. Hypocitraturia: Kidney Stones - Medical and Surgical Management. Lippincott-Raven Publishers, Philadelphia 1996; 905.
27. Preminger GM, Harvey JA and Pak CYC. Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity. J Urol 1985; 134:658.
28. Ahstrand C, Tiselius HG. Recurrences during a 10 years follow-up after the first renal episode. Urol Res 1990; 18:397.
29. Ettinger B, Paj CYC, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium titrate is an effective prophylaxis against recurrent caldum oxalate nephrolithiasis. J Urol 1997; 158:2069. (Pubitemid 27481329)
30. Siener R, Glatz S, Nicolay C, Hesse A. A prospective study on the Efficacy of a Selective Treatment and Risk factors relapse in recurrent Calcium Oxalate Stone Patients. European Urol 2003; 44:467. (Pubitemid 37185674)
31. Strohmaier WL Corse of calcium disease without treatment. What can we expect? Eur Urol 2000; 37:339.
32. Tiselius HG. Factors influencing the course of caldum oxalate stone disease. Eur Urol 1999; 36:363.
33. Lieske JC, Coe FL. Urinary inhibitors and renal stone formation. In: Preminger GM, ed. Kidney stones: Medical and Surgical treatment. Philadelphia: Lippincott-Raven, 1996; 1:65-113.
34. Hess B, Zipperle L, Jaeger P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 1993; 265(6 Pt 2)1784-1789 (Pubitemid 24027585)
35. Yasui T. Sato M, Fujita K Effects of citrate on renal stone formation and osteopontin expression in a rat urolithiasis model. Urol Res 2001; 29:50. (Pubitemid 32216729)
36. Churchill DN. Medical treatment to prevent recunent calcium urolithiasis. Mineral Electrolyte Metab 1987; 13:294.
37. Mottle D, Hess B. Preventive treatment of nephrolithiasis with alkali citrate - a critical review. Urol Res 2005; 33:73. (Pubitemid 40921945)
38. Caudarella R. Trattamento Medico della Nefrolitiasi e delle sue Recidive III° Congresso Nazionale di Fitoterapia in Urologia ed Andrologia". Focus sulla Urolitiasi Forli 13 Maggio 2006 (oral presentation).